Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Patricia Avellana"'
Autor:
Claudio Hadid, Patricia Avellana, Darío Di Toro, Claudia Fernández Gomez, Miguel Visser, Noemí Prieto
Publikováno v:
Arquivos Brasileiros de Cardiologia, Vol 90, Iss 5, Pp 339-344 (2008)
FUNDAMENTO: Os recentes estudos MADIT II e SCD-HeFT levaram a uma expansão das indicações do uso profilático de cardiodesfibrilador implantável (CDI) em pacientes com grave disfunção ventricular esquerda. Essa terapia não foi totalmente adota
Externí odkaz:
https://doaj.org/article/978bd5cebecd47d29f089261e1e09012
Autor:
Fernando Dominguez, Patricia Avellana, Pablo García-Pavía, Gonzalo Guzzo-Merello, Isabel Millán, Javier Segovia, Luis Alonso-Pulpón, Marta Cobo-Marcos, Manuel Gómez-Bueno
Publikováno v:
JACC: Heart Failure. 3:78-86
Objectives This study sought to determine the natural history of contemporary alcoholic cardiomyopathy (ACM), to compare it with that of idiopathic dilated cardiomyopathy (IDCM), and to identify risk factors for poor outcome. Background ACM is a comm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67f8a605c5432e9d4eeb40c4bbee3658
https://doi.org/10.1016/j.jchf.2014.07.014
https://doi.org/10.1016/j.jchf.2014.07.014
Publikováno v:
The Journal of Heart and Lung Transplantation. 37:429-430
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::94977585dcbeb297ef8de65d6bef95bf
https://doi.org/10.1016/j.healun.2017.10.020
https://doi.org/10.1016/j.healun.2017.10.020
Autor:
María Dolores García-Cosío Carmena, Javier Segovia, Luis Alonso-Pulpón, Manuel Gómez-Bueno, Patricia Avellana, Francisco J. López
Publikováno v:
Cardiocore. 47:154-160
Resumen La hipertension pulmonar (HTP) es una enfermedad de baja prevalencia que puede afectar a mujeres en edad fertil. Segun las distintas series, en estas pacientes la mortalidad materna durante el embarazo oscila entre el 30 y el 50%. La mayoria
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::96539a74f300d1ecfb7154b29ef4e07d
https://doi.org/10.1016/j.carcor.2012.03.002
https://doi.org/10.1016/j.carcor.2012.03.002
Autor:
Luis Alonso-Pulpón, Javier Segovia, Xavier Borrás, Patricia Avellana, Andreu Ferrero, Juan Cinca, Josep Brugada, Rafael Vázquez
Publikováno v:
Revista Uruguaya de Cardiología, Volume: 28, Issue: 1, Pages: 111-111, Published: APR 2013
ResearcherID
ResearcherID
A B S T R A C T Introduction and objectives: In patients with heart failure, left ventricular ejection fraction 35% and sinus rhythm without conditions such as atrial fibrillation, thrombus or history of thromboembolic events, the use of anticoagulat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b43b78da82b2d12d5ed561f9a63746c
https://doi.org/10.1016/j.recesp.2011.11.012
https://doi.org/10.1016/j.recesp.2011.11.012
Autor:
Clara Salas, Manuel Gómez-Bueno, Rafael Garesse, Maria E. Vázquez, Javier Segovia, Jesús Molano, Belén Bornstein, Patricia Avellana, Pablo García-Pavía, Luis Alonso-Pulpón, M. Esther Gallardo, Carlos Vilches
Publikováno v:
Digital.CSIC. Repositorio Institucional del CSIC
instname
instname
[Aims]: Hypertrophic cardiomyopathy (HCM) is characterized by a heterogeneous presentation and clinical course. A minority of HCM patients develop end-stage HCM and require cardiac transplantation. The genetic basis of end-stage HCM is unknown but sm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f329c66f1f997b53949450a0b71b83e
https://doi.org/10.1093/eurjhf/hfr110
https://doi.org/10.1093/eurjhf/hfr110
Autor:
Elena Pérez Pereira, Elena Sufrate, Luis Alonso-Pulpón, Javier Segovia, Pablo García-Pavía, Carlos Gutiérrez Landaluce, María Dolores García-Cosío Carmena, Manuel Gómez-Bueno, Patricia Avellana
Publikováno v:
Revista Española de Cardiología. 64:667-673
Introduction and objectives: Bosentan has proven efficacy in pulmonary hypertension in the short term. Little is known about its effects beyond 2 to 3 years. Our objective was to analyze the efficacy and safety of bosentan in the long term (5 years)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::187a063634b0328990c3011de860166c
https://doi.org/10.1016/j.recesp.2011.04.016
https://doi.org/10.1016/j.recesp.2011.04.016
Autor:
Carlos Gutiérrez Landaluce, Patricia Avellana, Elena Pérez Pereira, Elena Sufrate, Pablo García-Pavía, Manuel Gómez-Bueno, Javier Segovia, María Dolores García-Cosío Carmena, Luis Alonso-Pulpón
Publikováno v:
Revista Española de Cardiología (English Edition). 64:667-673
Introduction and objectives Bosentan has proven efficacy in pulmonary hypertension in the short term. Little is known about its effects beyond 2 to 3 years. Our objective was to analyze the efficacy and safety of bosentan in the long term (5 years) i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc316f9f604883fadc440aeebfdfd30c
https://doi.org/10.1016/j.rec.2011.04.015
https://doi.org/10.1016/j.rec.2011.04.015
Autor:
Javier Segovia, Damián Heine-Suñer, Luis Alonso-Pulpón, Belén Bornstein, Manuel Gómez-Bueno, Pablo García-Pavía, Patricia Avellana, Marta Cobo-Marcos
Publikováno v:
Revista Española de Cardiología. 64:523-526
Cardiac amyloidosis is a disease of complex diagnosis and treatment. Some subtypes of cardiac amyloidosis are inherited. Among these, the most common variant is caused by mutations in the transthyretin gene. Correct identification of amyloidosis prod
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2bd8e904e64a9b2314b556240fb61221
https://doi.org/10.1016/j.recesp.2010.10.018
https://doi.org/10.1016/j.recesp.2010.10.018
Autor:
Patricia Avellana, Javier Segovia, Damián Heine-Suñer, Marta Cobo-Marcos, Pablo García-Pavía, Manuel Gómez-Bueno, Luis Alonso-Pulpón, Belén Bornstein
Publikováno v:
Revista Española de Cardiología (English Edition). 64:523-526
Cardiac amyloidosis is a disease of complex diagnosis and treatment. Some subtypes of cardiac amyloidosis are inherited. Among these, the most common variant is caused by mutations in the transthyretin gene. Correct identification of amyloidosis prod
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c90fb974fbd9b2fd0eaadcb0ab0f522e
https://doi.org/10.1016/j.rec.2010.12.005
https://doi.org/10.1016/j.rec.2010.12.005